<DOC>
	<DOCNO>NCT01232530</DOCNO>
	<brief_summary>This phase IV open label study assess safety effectiveness artemisinin derivatives-based combination therapy ( ACT ) use large scale `` real life '' condition .</brief_summary>
	<brief_title>Pharmacovigilance ACTs Africa</brief_title>
	<detailed_description>The study conduct well define population Burkina Faso set population-based monitoring system . The monitoring adverse event ( AEs ) use two approach ( active passive ) base repeat survey study population . The active surveillance population weekly actively visited home day 7 , day 14 day 28 drug administration . The passive surveillance population encourage report passively AE/ADR NOT actively visit home . In addition , possible exposure ACTs pregnant woman identify repeat survey active passive surveillance area extract drug exposure log book elicit history , data enter pregnancy register . For effectiveness study , patient microscopically confirm diagnosis malaria ( parasite density ) , clinical symptom blood sample thick thin blood smear , later PCR analysis ( filter paper ) genotyping collect antimalarial treatment , day 28 treatment unscheduled visit . This repeat confirmed malaria episode .</detailed_description>
	<criteria>Males Females live Nanoro DSS catchment area ; Signed ( thumbprinted whenever patient illiterate ) inform consent . Patients ' willingness ability comply study protocol duration study . Severe malaria . Danger sign : able drink breastfeed , vomit ( &gt; twice 24hours ) , recent history convulsion ( &gt; 1 24h ) , unconscious state , unable sit stand .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Malria , ACT , Safety , Efficacy , pregarnancy</keyword>
</DOC>